Aktienanalyse zu Aquestive Therapeutics, Inc. (AQST)AQSTAquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Aquestive Therapeutics Inc (AQST) is not a good buy. The stock is trading at $3.78, which is significantly below the analyst price target of $8, indicating potential upside. However, the stock has a very low RSI of 12.312, suggesting it is oversold, but this is accompanied by a concerning trend with a 5-day change of -20.92% and a year-to-date change of -41.40%. The recent insider selling has increased by 140.84%, which raises concerns about insider confidence in the company's future. The main risk is the negative net income, which was -22.9 million in Q2 2026, indicating ongoing financial struggles.

4 analysts cover AQST: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.00.